ArticleFrontiers in oncology2026
Trends and projections of global testicular cancer burden from 1990 to 2035.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Testicular cancer (TC) is the most common malignancy in young men, with incidence increasing globally, especially in high-income countries. Although survival has improved due to advances in diagnosis and treatment, disparities in TC burden remain. This study analyzes global, regional, and national trends in TC incidence, mortality, and disability-adjusted life years (DALYs) from 1990 to 2021, and projects future trends to 2035. Methods: Data were obtained from the Global Burden of Disease (GBD) 2021 database. Incidence, mortality, and DALY rates per 100,000 population were calculated with 95% uncertainty intervals (UIs). Trend analysis used Joinpoint regression and estimated annual percentage change (EAPC). Decomposition analysis identified drivers of burden changes. A Bayesian age-period-cohort (BAPC) model projected future burden. Results: In 2021, there were 91,507 TC cases, 11,388 deaths, and 560,921 DALYs globally. From 1990 to 2021, cases rose by 136%, deaths by 49%, and DALYs by 44%. Incidence increased from 1.45 to 2.31 per 100,000. The middle socio-demographic index (SDI) region showed the highest EAPCs for incidence (4.34%), mortality (1.07%), and DALYs (0.92%). The Caribbean had the fastest-growing incidence (EAPC = 5.71%). Nationally, the U.S. had the most cases (11,845), Monaco the highest incidence (32.89/100,000), and Qatar the steepest rise (EAPC = 10.25%). By 2035, incidence is projected to rise further, while mortality and DALY rates may decline. Conclusion: The global burden of TC has increased markedly since 1990, especially in middle-SDI regions and the Caribbean. Although some areas have seen improvements, rising incidence highlights the need for targeted prevention and optimized care strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.